Quick Answer
Curanex Pharmaceuticals Inc reported Stockholders Equity of $11.22 million for fiscal year 2025.
Curanex Pharmaceuticals Inc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $11.22M | +2128.8% |
| 2024 | $503.4K | +737.7% |
| 2023 | $60.1K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.29M | +2189.8% | +4579.4% |
| June 30, 2025 | $305.4K | -57.3% | -16.5% |
| March 31, 2025 | $365.8K | +181.6% | -27.3% |
| December 31, 2024 | $503.4K | +737.7% | -19.4% |
| September 30, 2024 | $624.2K | — | -12.7% |
| June 30, 2024 | $715.2K | — | +450.7% |
| March 31, 2024 | $129.9K | — | +116.2% |
| December 31, 2023 | $60.1K | — | — |
- Curanex Pharmaceuticals Inc showed an increase of +2128.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2023–2025 period, Curanex Pharmaceuticals Inc’s stockholders equity has grown by 18570.5% (from $60.1 thousand to $11.22 million).
- The most recent figure is from Curanex Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: